Detalhe da pesquisa
1.
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
Am J Gastroenterol
; 2024 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38095692
2.
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med
; 381(13): 1201-1214, 2019 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31553833
3.
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
Clin Gastroenterol Hepatol
; 20(12): 2858-2867.e5, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35276329
4.
Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments.
Gut
; 70(2): 418-426, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32699100
5.
Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
Gastroenterology
; 159(6): 2052-2064, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32853634
6.
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 18(10): 2244-2255.e9, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31816446
7.
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Reply.
N Engl J Med
; 382(1): 91, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31875505
8.
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Gastroenterology
; 147(6): 1296-1307.e5, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25173754
9.
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Gastroenterology
; 146(1): 96-109.e1, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23770005
10.
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Gastroenterology
; 146(1): 85-95; quiz e14-5, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23735746
11.
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
J Am Acad Dermatol
; 73(4): 594-603, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26259989
12.
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
J Crohns Colitis
; 2024 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38310565
13.
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Gastroenterology
; 141(4): 1194-201, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21723220
14.
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
J Crohns Colitis
; 16(8): 1222-1234, 2022 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35239968
15.
Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis.
Am J Gastroenterol
; 106(7): 1272-80, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21448149
16.
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI).
Intest Res
; 19(4): 386-397, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33249802
17.
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.
Inflamm Bowel Dis
; 27(7): 994-1007, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32964215
18.
Opioid Use in Patients With Inflammatory Bowel Disease.
Crohns Colitis 360
; 2(1): otaa009, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36777960
19.
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
Aliment Pharmacol Ther
; 52(11-12): 1658-1675, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33086438
20.
A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials.
J Crohns Colitis
; 13(8): 1025-1035, 2019 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30721964